Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Method

Showing results (11-20 of 23) with videos related to

Pageof 3
Sort By:
The Lancet. Oncology|February 5, 2017
A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort studyEmma C Rossi, Lynn D Kowalski, Jennifer Scalici, et al.
Gynecologic Oncology|July 23, 2025
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancerUrsula A Matulonis, Ignace Vergote, Kathleen N Moore, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|April 6, 2022
A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy AloneMonika D Polewski, Gitte B Nielsen, Ying Gu, et al.
Gynecologic Oncology|February 3, 2023
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerLucy Gilbert, Ana Oaknin, Ursula A Matulonis, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 10, 2024
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trialRobert L Coleman, Domenica Lorusso, Ana Oaknin, et al.
Gynecologic Oncology|March 6, 2024
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancerDebra L Richardson, Kathleen N Moore, Ignace Vergote, et al.
Gynecologic Oncology|October 13, 2015
Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group studyLisa M Hess, Helen Q Huang, Alexandra L Hanlon, et al.
Gynecologic Oncology|January 10, 2020
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II studyMolly Brewer, Roberto Angioli, Giovani Scambia, et al.
The Lancet. Oncology|February 2, 2015
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)Richard T Penson, Helen Q Huang, Lari B Wenzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2023
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA StudyUrsula A Matulonis, Domenica Lorusso, Ana Oaknin, et al.
Pageof 3

Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
The Lancet. Oncology|February 5, 2017
A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort studyEmma C Rossi, Lynn D Kowalski, Jennifer Scalici, et al.
Gynecologic Oncology|July 23, 2025
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancerUrsula A Matulonis, Ignace Vergote, Kathleen N Moore, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|April 6, 2022
A Standardized Investigational Ki-67 Immunohistochemistry Assay Used to Assess High-Risk Early Breast Cancer Patients in the monarchE Phase 3 Clinical Study Identifies a Population With Greater Risk of Disease Recurrence When Treated With Endocrine Therapy AloneMonika D Polewski, Gitte B Nielsen, Ying Gu, et al.
Gynecologic Oncology|February 3, 2023
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancerLucy Gilbert, Ana Oaknin, Ursula A Matulonis, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|June 10, 2024
Mirvetuximab soravtansine in folate receptor alpha (FRα)-high platinum-resistant ovarian cancer: final overall survival and post hoc sequence of therapy subgroup results from the SORAYA trialRobert L Coleman, Domenica Lorusso, Ana Oaknin, et al.
Gynecologic Oncology|March 6, 2024
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancerDebra L Richardson, Kathleen N Moore, Ignace Vergote, et al.
Gynecologic Oncology|October 13, 2015
Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group studyLisa M Hess, Helen Q Huang, Alexandra L Hanlon, et al.
Gynecologic Oncology|January 10, 2020
Front-line chemo-immunotherapy with carboplatin-paclitaxel using oregovomab indirect immunization in advanced ovarian cancer: A randomized phase II studyMolly Brewer, Roberto Angioli, Giovani Scambia, et al.
The Lancet. Oncology|February 2, 2015
Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)Richard T Penson, Helen Q Huang, Lari B Wenzel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 30, 2023
Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA StudyUrsula A Matulonis, Domenica Lorusso, Ana Oaknin, et al.
Pageof 3